<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<rss version="2.0">
<channel>
<title>Abbott MediaRoom</title>
<link>https://abbott.mediaroom.com/</link>
<description></description>
<item>
<title>Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer</title>
<link>https://abbott.mediaroom.com/2026-10-23-Abbott-presents-new-ESMO-data-showing-30-percent-absolute-improvement-in-sensitivity-with-the-whole-genome-sequencing-Oncodetect-R-test-in-colorectal-cancer</link>
<description></description>
<pubDate>Fri, 23 Oct 2026 09:15:00 -0400</pubDate>
<guid>https://abbott.mediaroom.com/2026-10-23-Abbott-presents-new-ESMO-data-showing-30-percent-absolute-improvement-in-sensitivity-with-the-whole-genome-sequencing-Oncodetect-R-test-in-colorectal-cancer</guid>
<enclosure url="https://mma.prnewswire.com/media/2761216/Abbott_New_Logo.jpg?p=thumbnail" type="image/jpeg" />
</item>
<item>
<title>Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance</title>
<link>https://abbott.mediaroom.com/2026-10-21-Abbott-Reports-Third-Quarter-2026-Results-and-Reaffirms-Full-Year-EPS-Guidance</link>
<description></description>
<pubDate>Wed, 21 Oct 2026 07:30:00 -0400</pubDate>
<guid>https://abbott.mediaroom.com/2026-10-21-Abbott-Reports-Third-Quarter-2026-Results-and-Reaffirms-Full-Year-EPS-Guidance</guid>
<enclosure url="https://mma.prnewswire.com/media/2761216/Abbott_New_Logo.jpg?p=thumbnail" type="image/jpeg" />
</item>
<item>
<title>Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company</title>
<link>https://abbott.mediaroom.com/2026-10-21-Abbott-announces-its-intention-to-separate-its-global-Nutrition-business-into-an-independent,-publicly-traded-company</link>
<description></description>
<pubDate>Wed, 21 Oct 2026 07:25:00 -0400</pubDate>
<guid>https://abbott.mediaroom.com/2026-10-21-Abbott-announces-its-intention-to-separate-its-global-Nutrition-business-into-an-independent,-publicly-traded-company</guid>
<enclosure url="https://mma.prnewswire.com/media/2761216/Abbott_New_Logo.jpg?p=thumbnail" type="image/jpeg" />
</item>
<item>
<title>Abbott&apos;s Cologuard Plus® receives CE Mark for colorectal cancer screening in Europe</title>
<link>https://abbott.mediaroom.com/2026-10-20-Abbotts-Cologuard-Plus-R-receives-CE-Mark-for-colorectal-cancer-screening-in-Europe</link>
<description></description>
<pubDate>Tue, 20 Oct 2026 02:00:00 -0400</pubDate>
<guid>https://abbott.mediaroom.com/2026-10-20-Abbotts-Cologuard-Plus-R-receives-CE-Mark-for-colorectal-cancer-screening-in-Europe</guid>
<enclosure url="https://mma.prnewswire.com/media/2761216/Abbott_New_Logo.jpg?p=thumbnail" type="image/jpeg" />
</item>
<item>
<title>Abbott launches ‘Mind Your Behind’ campaign to encourage Americans 45+ to screen for colorectal cancer</title>
<link>https://abbott.mediaroom.com/2026-10-13-Abbott-launches-Mind-Your-Behind-campaign</link>
<description></description>
<pubDate>Tue, 13 Oct 2026 08:00:00 -0400</pubDate>
<guid>https://abbott.mediaroom.com/2026-10-13-Abbott-launches-Mind-Your-Behind-campaign</guid>
</item>
</channel>
</rss>
